Ventyx Biosciences (VTYX)
(Real Time Quote from BATS)
$2.10 USD
-0.14 (-6.25%)
Updated Aug 2, 2024 02:54 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Ventyx Biosciences, Inc. (VTYX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.80 | $48.00 | $5.00 | 560.71% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Ventyx Biosciences, Inc. comes to $14.80. The forecasts range from a low of $5.00 to a high of $48.00. The average price target represents an increase of 560.71% from the last closing price of $2.24.
Analyst Price Targets (10)
Broker Rating
Ventyx Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.73 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.73 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, seven are Strong Buy, representing 63.64% of all recommendations. A month ago, Strong Buy represented 63.64%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.73 | 1.73 | 1.73 | 1.73 | 1.73 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/29/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
6/6/2024 | H.C. Wainwright & Co. | Emily Bodnar | Hold | Hold |
6/5/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
5/10/2024 | Not Identified | Not Identified | Hold | Hold |
3/13/2024 | Canaccord Genuity | Edward H Nash | Strong Buy | Strong Buy |
3/12/2024 | Wells Fargo Securities | Derek C Archila | Hold | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/1/2023 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
11/10/2023 | Evercore Partners | Gavin Clark-Gartner | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.73 |
ABR (Last week) | 1.73 |
# of Recs in ABR | 11 |
Average Target Price | $14.80 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 88 of 253 |
Current Quarter EPS Est: | -0.57 |